FATE THERAPEUTICS INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
FATE THERAPEUTICS INC (FATE) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$43.84 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$43.84M.
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $13.20M, a 120.86% increase year-over-year.
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $13.64M, a 2877.73% increase year-over-year.
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $1.34M, a 76.89% decline year-over-year.
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$10.20M.
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$4.11M.
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$1.50M.
- FATE THERAPEUTICS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$882.00K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 77 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 80 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 83 month |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$43.84M 10-Q · filed 2018-05-10 | -$30.64M derived: sum of 2 quarters · filed 2018-05-10 | -$17.00M derived: sum of 3 quarters · filed 2018-05-10 | -$15.66M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $26.84M derived: sum of 2 quarters · filed 2018-03-05 | $28.18M derived: sum of 3 quarters · filed 2018-03-05 | -$10.20M 10-K · filed 2018-03-05 | |||
| 2017-09-30 | $13.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $14.98M derived: sum of 2 quarters · filed 2017-11-01 | -$23.40M 10-Q · filed 2017-11-01 | -$17.42M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$37.04M 10-Q · filed 2017-08-14 | -$31.06M derived: sum of 3 quarters · filed 2018-05-10 | -$30.60M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2017-03-31 | -$38.38M 10-Q · filed 2018-05-10 | -$32.40M derived: sum of 2 quarters · filed 2018-05-10 | -$31.94M derived: sum of 3 quarters · filed 2018-05-10 | -$26.15M derived: sum of 4 quarters · filed 2018-05-10 | |||
| 2016-12-31 | $5.98M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | $6.44M derived: sum of 2 quarters · filed 2018-03-05 | $12.23M derived: sum of 3 quarters · filed 2018-03-05 | -$4.11M 10-K · filed 2018-03-05 | |||
| 2016-09-30 | $458.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $6.25M derived: sum of 2 quarters · filed 2017-11-01 | -$10.09M 10-Q · filed 2017-11-01 | -$10.27M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-06-30 | $5.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$10.55M 10-Q · filed 2017-08-14 | -$10.73M derived: sum of 3 quarters · filed 2018-03-05 | -$11.38M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2016-03-31 | -$16.34M 10-Q · filed 2017-05-15 | -$16.52M derived: sum of 2 quarters · filed 2018-03-05 | -$17.18M derived: sum of 3 quarters · filed 2018-03-05 | -$17.39M derived: sum of 4 quarters · filed 2018-03-05 | |||
| 2015-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-05 | -$833.00K derived: sum of 2 quarters · filed 2018-03-05 | -$1.05M derived: sum of 3 quarters · filed 2018-03-05 | -$1.50M 10-K · filed 2018-03-05 | |||
| 2015-09-30 | -$655.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$868.00K derived: sum of 2 quarters · filed 2016-11-07 | -$1.32M 10-Q · filed 2016-11-07 | -$1.59M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-06-30 | -$213.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | -$665.00K 10-Q · filed 2016-08-08 | -$936.00K derived: sum of 3 quarters · filed 2017-03-16 | -$1.12M derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2015-03-31 | -$452.00K 10-Q · filed 2016-05-09 | -$723.00K derived: sum of 2 quarters · filed 2017-03-16 | -$910.00K derived: sum of 3 quarters · filed 2017-03-16 | -$936.00K derived: sum of 4 quarters · filed 2017-03-16 | |||
| 2014-12-31 | -$271.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$458.00K derived: sum of 2 quarters · filed 2017-03-16 | -$484.00K derived: sum of 3 quarters · filed 2017-03-16 | -$882.00K 10-K · filed 2017-03-16 | |||
| 2014-09-30 | -$187.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | -$213.00K derived: sum of 2 quarters · filed 2015-11-03 | -$611.00K 10-Q · filed 2015-11-03 | -$761.00K derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$424.00K 10-Q · filed 2015-08-05 | -$574.00K derived: sum of 3 quarters · filed 2016-03-03 | -$591.00K derived: sum of 4 quarters · filed 2016-03-03 | |||
| 2014-03-31 | -$398.00K 10-Q · filed 2015-05-07 | -$548.00K derived: sum of 2 quarters · filed 2016-03-03 | -$565.00K derived: sum of 3 quarters · filed 2016-03-03 | -$629.00K derived: sum of 4 quarters · filed 2016-03-03 | -$3.97M 10-Q · filed 2014-05-13 | ||
| 2013-12-31 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-03 | -$167.00K derived: sum of 2 quarters · filed 2016-03-03 | -$231.00K derived: sum of 3 quarters · filed 2016-03-03 | -$238.00K 10-K · filed 2016-03-03 | -$3.58M 10-K · filed 2014-03-17 | ||
| 2013-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$81.00K derived: sum of 2 quarters · filed 2014-11-12 | -$88.00K 10-Q · filed 2014-11-12 | -$383.00K derived: sum of 4 quarters · filed 2015-03-12 | -$3.42M 10-Q · filed 2013-11-13 | ||
| 2013-06-30 | -$64.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-12 | -$71.00K 10-Q · filed 2014-08-12 | -$366.00K derived: sum of 3 quarters · filed 2015-03-12 | ||||
| 2013-03-31 | -$7.00K 10-Q · filed 2014-05-13 | -$302.00K derived: sum of 2 quarters · filed 2015-03-12 | |||||
| 2012-12-31 | -$295.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | -$709.00K 10-K · filed 2015-03-12 | |||||
| 2012-09-30 | -$414.00K 10-Q · filed 2013-11-13 | ||||||
| 2011-12-31 | $200.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |